Compare Research Peptides

Select 2 peptides to compare benefits, dosage, administration routes, mechanisms, and side effect profiles side by side.

Peptide 1

Peptide 2

	Thymosin Alpha-1 TA1 Sign up to track	LL-37 Cathelicidin Sign up to track
Evidence Grade	BEvidenceGrade BSmaller human trials, observational studies, or approved in 30+ countries	CEvidenceGrade CPrimarily animal or in-vitro studies; limited human data
Regulatory	CompoundableCompoundableLegal to compound in the US; approved in other jurisdictions or has historical approval	Research OnlyResearch OnlyNo regulatory approval in any major jurisdiction; for research use only
Category	Immune & Inflammatory Modulation	Immune & Inflammatory Modulation
Key Benefits	•Immune system modulation and enhancement •Antiviral properties •Used in hepatitis B and C treatment •Cancer adjuvant therapy +3 more	•Broad-spectrum antimicrobial effects •Modulates immune response •Promotes wound healing •Anti-inflammatory properties +2 more
Dosage	0.8-3.2 mg mg	5-10 mg mg
Frequency	2-3x per week	2-3x weekly
Administration	Subcutaneous	SubcutaneousIntramuscular
Mechanism	Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a central role in immune function. It modulates the immune system, enhances T-cell function, and has been used as an adjuvant therapy for various conditions including hepatitis and cancer.	LL-37 is the only human cathelicidin, a natural antimicrobial peptide with broad-spectrum activity. It plays a crucial role in innate immunity and wound healing.
Side Effects / Risks	Not specified	Not specified
Research Status	Approved in some countries (not FDA approved in US)	Research compound